A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’s delivered—injecting it directly into tumors instead of into the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission.

Summary:

A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’s delivered—injecting it directly into tumors instead of into the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission.

  • Hirom ( Hirom@beehaw.org ) 
    2·
    7 months ago

    For approval, a new treatment has to show it’s better than already approved treatments. Not better than nothing.

    This appear to target difficult to treat cancer so any result is encouraging, especially in a clinical trial.